Articles

Digging into diversity

GSK, Novartis kick off collaboration to explore how genetic diversity in Africa impacts treatment response
Brought to you byDDNews Staff
| 3 min read

LONDON—A collaboration is now underway between GlaxoSmithKline (GSK) and Novartis supporting high-quality research investigating how genetic diversity across different regions in Africa could impact patients' responses to drug therapeutics. The project—Africa Genomic Research Approach for Diversity and Optimising Therapeutics (GRADIENT)—will have a combined funding commitment of GBP 2.8m (USD 3.6 million) over the course of five years, and is soliciting research proposals from African researchers on how African genetic diversity impacts treatment for malaria and tuberculosis.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.
3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.
3D illustration of a multicolored protein structure composed of folded ribbon-like strands against a blue and teal background with scattered spherical particles
Learn how advanced analytical methods support the characterization of antibody–C1q interactions and the qualification of analytical binding assays.